You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 6,911,461

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,911,461 protect, and when does it expire?

Patent 6,911,461 protects BRIVIACT and is included in three NDAs.

This patent has one hundred and forty-six patent family members in forty-two countries.

Summary for Patent: 6,911,461

Patent landscape, scope, and claims:

Title:	2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
Abstract:	The invention concerns 2-oxo-1-pyrrolidine derivatives of formula I, ##STR1## wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention are particularly suited for treating neurological disorders such as epilepsy.
Inventor(s):	Differding; Edmond (Louvain-la Neuve, BE), Kenda; Benoit (Emines, BE), Lallemand; Benedicte (Waimes, BE), Matagne; Alain (Gerpinnes, BE), Michel; Philippe (Beersel, BE), Pasau; Patrick (Chastre, BE), Talaga; Patrice (Watermael-Boitsfort, BE)
Assignee:	UCB, S.A. (Brussels, BE)
Application Number:	10/693,917
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,911,461
Patent Claim Types: see list of patent claims	Compound; Composition; Use;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 6,911,461

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;INTRAVENOUS	205837-001	May 12, 2016		RX	Yes	Yes	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	SOLUTION;ORAL	205838-001	May 12, 2016		RX	Yes	Yes	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-001	May 12, 2016		RX	Yes	No	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-002	May 12, 2016		RX	Yes	No	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER	⤷ Subscribe
Ucb Inc	BRIVIACT	brivaracetam	TABLET;ORAL	205836-003	May 12, 2016		RX	Yes	No	6,911,461	⤷ Subscribe	Y	Y		TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 6,911,461

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0004297	Feb 23, 2000

International Family Members for US Patent 6,911,461

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1265862	⤷ Subscribe	PA2016013	Lithuania	⤷ Subscribe
European Patent Office	1452524	⤷ Subscribe	300815	Netherlands	⤷ Subscribe
European Patent Office	1452524	⤷ Subscribe	CA 2016 00013	Denmark	⤷ Subscribe
European Patent Office	1452524	⤷ Subscribe	16C1001	France	⤷ Subscribe
European Patent Office	1452524	⤷ Subscribe	1690009-4	Sweden	⤷ Subscribe
European Patent Office	1265862	⤷ Subscribe	PA2016013,C1265862	Lithuania	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.